Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28 ILa | +0.36% | -6.35% | -26.70% |
Mar. 26 | Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024 | |
Mar. 26 | BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2023 | 4.8M 1.77B | Sales 2024 * | 14.36M 5.28B | Capitalization | 82.97M 30.51B |
---|---|---|---|---|---|
Net income 2023 | -60M -22.06B | Net income 2024 * | -47M -17.28B | EV / Sales 2023 | 23.9 x |
Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 5.78 x |
P/E ratio 2023 |
-1.76
x | P/E ratio 2024 * |
-3.82
x | Employees | 49 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 100% |
Latest transcript on BioLineRx Ltd.
1 day | +0.36% | ||
1 week | -6.35% | ||
Current month | -12.23% | ||
1 month | -11.11% | ||
3 months | -27.08% | ||
6 months | -42.27% | ||
Current year | -26.70% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 09-05-23 | |
Mali Zeevi
DFI | Director of Finance/CFO | 48 | 08-12-31 |
Irit Gliko-Kabir
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sandra Panem
BRD | Director/Board Member | 77 | 14-02-23 |
Michael Anghel
BRD | Director/Board Member | 85 | 10-08-31 |
Avraham Molcho
BRD | Director/Board Member | 66 | 09-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 28 | +0.36% | 866,531 |
24-03-27 | 27.9 | -4.78% | 3,449,825 |
24-03-26 | 29.3 | -11.75% | 4,642,403 |
24-03-25 | 33.2 | +11.04% | 2,148,510 |
24-03-21 | 29.9 | +2.75% | 604,346 |
Delayed Quote TEL AVIV STOCK EXCHANGE, March 28, 2024 at 11:24 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.70% | 82.97M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |